Oral 5‐ASA vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with comparator 5‐ASA (low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes onlyRR 0.59 [0.22, 1.56]4 studies · 677 participantsLow